Literature DB >> 1301360

Pharmacokinetics of nefazodone in the dog following single oral administration.

U A Shukla1, P H Marathe, J A Labudde, K A Pittman, R H Barbhaiya.   

Abstract

The pharmacokinetics of nefazodone (NEF) and two of its pharmacologically active metabolites viz hydroxynefazodone (HO-NEF) and m-chlorophenylpiperazine (mCPP) were determined following single oral administration of 100, 200 and 400 mg NEF to 6 beagle dogs in a three-way crossover study. Blood samples were collected for 48 h and plasma was analyzed for NEF, HO-NEF and mCPP by a validated HPLC assay. NEF was rapidly absorbed after oral administration. Cmax values for all three compounds and AUCinf values for HO-NEF and mCPP were dose-proportional; AUCinf values for NEF were dose-linear but not dose-proportional. The T1/2 values for NEF and HO-NEF following the 400 mg dose were significantly greater than those for the 100 mg dose. No differences in mCPP T1/2 were observed among the doses. The Cmax and AUCinf ratios for metabolite:NEF were about 2-fold lower for the 200 and 400 mg doses than those observed for the 100 mg dose. However, due to extensive variability, the ratios for three doses were not significantly different based on statistical analysis. Overall, these data suggest the pharmacokinetics of NEF are dose-dependent in the beagle dog. Statistical significance for dose-dependency for many of the pharmacokinetic parameters could not be demonstrated due to high variability associated with the plasma concentration vs time profiles.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1301360     DOI: 10.1007/BF03190163

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  5 in total

1.  Placebo-controlled dose-ranging trial designs in phase II development of nefazodone.

Authors:  M F D'Amico; D L Roberts; D S Robinson; U E Schwiderski; J Copp
Journal:  Psychopharmacol Bull       Date:  1990

2.  The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time.

Authors:  S Riegelman; P Collier
Journal:  J Pharmacokinet Biopharm       Date:  1980-10

Review 3.  Nefazodone: preclinical pharmacology of a new antidepressant.

Authors:  A S Eison; M S Eison; J R Torrente; R N Wright; F D Yocca
Journal:  Psychopharmacol Bull       Date:  1990

4.  High-performance liquid chromatographic method for the determination of nefazodone and its metabolites in human plasma using laboratory robotics.

Authors:  J E Franc; G F Duncan; R H Farmen; K A Pittman
Journal:  J Chromatogr       Date:  1991-09-18

5.  A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression.

Authors:  J P Feighner; R Pambakian; R C Fowler; W F Boyer; M F D'Amico
Journal:  Psychopharmacol Bull       Date:  1989
  5 in total
  3 in total

Review 1.  Clinical pharmacokinetics of nefazodone.

Authors:  D S Greene; R H Barbhaiya
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

2.  Pharmacokinetics of nefazodone following multiple escalating oral doses in the dog.

Authors:  U A Shukla; S Kaul; P H Marathe; K A Pittman; R H Barbhaiya
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Oct-Dec       Impact factor: 2.441

Review 3.  Pharmacokinetic optimisation of therapy with newer antidepressants.

Authors:  P J Goodnick
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.